TY - JOUR
T1 - The Prison and Transition Health (PATH) cohort study
T2 - Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia
AU - Stewart, Ashleigh C.
AU - Cossar, Reece D.
AU - Wilkinson, Anna L.
AU - Quinn, Brendan
AU - Dietze, Paul
AU - Walker, Shelley
AU - Butler, Tony
AU - Curtis, Michael
AU - Aitken, Campbell
AU - Kirwan, Amy
AU - Winter, Rebecca
AU - Ogloff, James
AU - Kinner, Stuart
AU - Stoové, Mark
N1 - Funding Information:
MS has received investigator-initiated funding from Gilead Sciences , AbbVie, and Bristol Myers Squibb for research unrelated to this work. PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest.
Funding Information:
This work was supported by an Australian National Health and Medical Research Council (NHMRC) Project Grant ( APP1029915 ). MS and PD are supported by NHMRC senior research fellowships. We gratefully acknowledge the support provided to the Burnet Institute by the Victorian Government Operational Infrastructure Support Program. RDC and ACS are support by Research Training Program Stipend .
Funding Information:
This work was supported by an Australian National Health and Medical Research Council (NHMRC) Project Grant (APP1029915). MS and PD are supported by NHMRC senior research fellowships. We gratefully acknowledge the support provided to the Burnet Institute by the Victorian Government Operational Infrastructure Support Program. RDC and ACS are support by Research Training Program Stipend.MS has received investigator-initiated funding from Gilead Sciences, AbbVie, and Bristol Myers Squibb for research unrelated to this work. PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest.We gratefully acknowledge the support provided to the Burnet Institute by the Victorian Government Operational Infrastructure Support Program. The authors would also like to acknowledge the participants involved in the PATH Study for the time and knowledge they contributed. Thanks to the Burnet Institute fieldwork team for their tireless efforts with data collection. We would also like to acknowledge the Victorian Department of Justice and Community Safety for its support.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Background: People who inject drugs are overrepresented in prison and have diverse and complex health needs. However, outcomes after release from prison are poorly understood, limiting effective interventions supporting community reintegration. We describe the prevalence of socio-demographics, physical and mental health, alcohol and other drug use, and crime characteristics of men with histories of injecting drug use after their release from prison in Victoria, Australia. Methods: Data come from the Prison and Transition Health (PATH) prospective cohort study. Interviews were undertaken approximately three, 12, and 24 months after release from their index prison episode and were completed in the community, or in prison for those reimprisoned during the study. We present cross-sectional descriptive statistics for each follow-up wave of the PATH study. Results: Among 400 men recruited into PATH, 85 % (n = 336) completed at least one follow-up interview; 162 (42 %) completed all three interviews. Participants reported social disadvantage and health inequity, including high rates of unemployment, homelessness, and physical and mental health morbidities at each follow-up time point. Rapid return to illicit substance use was common, as was overdose (ranging 9 %–13 %), receptive syringe sharing (ranging 20 %–29 %), involvement in crime-related activities (ranging 49 %–58 %), and reimprisonment (ranging 22 %–50 %) over the duration of follow-up. Conclusion: Men in this study experienced substantial health and social challenges across a 24-month prospective follow-up period. Improved understanding of characteristics and experiences of this group after release from prison can inform more coordinated and continued care between prison and the community.
AB - Background: People who inject drugs are overrepresented in prison and have diverse and complex health needs. However, outcomes after release from prison are poorly understood, limiting effective interventions supporting community reintegration. We describe the prevalence of socio-demographics, physical and mental health, alcohol and other drug use, and crime characteristics of men with histories of injecting drug use after their release from prison in Victoria, Australia. Methods: Data come from the Prison and Transition Health (PATH) prospective cohort study. Interviews were undertaken approximately three, 12, and 24 months after release from their index prison episode and were completed in the community, or in prison for those reimprisoned during the study. We present cross-sectional descriptive statistics for each follow-up wave of the PATH study. Results: Among 400 men recruited into PATH, 85 % (n = 336) completed at least one follow-up interview; 162 (42 %) completed all three interviews. Participants reported social disadvantage and health inequity, including high rates of unemployment, homelessness, and physical and mental health morbidities at each follow-up time point. Rapid return to illicit substance use was common, as was overdose (ranging 9 %–13 %), receptive syringe sharing (ranging 20 %–29 %), involvement in crime-related activities (ranging 49 %–58 %), and reimprisonment (ranging 22 %–50 %) over the duration of follow-up. Conclusion: Men in this study experienced substantial health and social challenges across a 24-month prospective follow-up period. Improved understanding of characteristics and experiences of this group after release from prison can inform more coordinated and continued care between prison and the community.
KW - Injecting drug use
KW - Longitudinal cohort study
KW - Prison
UR - https://www.scopus.com/pages/publications/85114145502
U2 - 10.1016/j.drugalcdep.2021.108970
DO - 10.1016/j.drugalcdep.2021.108970
M3 - Article
C2 - 34488074
AN - SCOPUS:85114145502
SN - 0376-8716
VL - 227
JO - Drug and Alcohol Dependence
JF - Drug and Alcohol Dependence
M1 - 108970
ER -